Publication | Closed Access

Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study

Phase 1/2Malignant DiseaseMedicineCancer ManagementPathologyMolecular OncologyPharmacotherapyCancer TreatmentOncologyRadiation OncologyCancer Research